��������

Komel Grover is an accomplished executive with extensive experience in strategic development and medical communications within the biopharmaceutical industry. Currently serving as President & CEO of Swiss American since July 2016, Komel Grover oversees strategic development, research and development, and innovations while leading corporate strategy for the parent company and its two divisions. Prior to this role, Komel Grover held senior positions at Smith-Nephew, Healthpoint Biotherapeutics, CV Therapeutics, Biogen, and KPMG, demonstrating a strong background in strategic initiatives, medical education, and business planning. Komel Grover holds two Master of Business Administration degrees in International Business, one from Pepperdine Graziadio Business School and another from EM Strasbourg Business School, complemented by ongoing education at The University of Texas Health Science Center at Houston.